Icon

AVAPRO (nda020757)- (75MG,150MG,300MG)

IRBESARTAN SANOFI AVENTIS US
75MG,150MG,300MG
Yes No
2015-Dec-07 Expired
None None
None No
AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria.
16 0 12
Total Other Developers 8
Drugs with Suitability No
75MG ** ** - - 6
150MG ** ** Up - 7
300MG ** ** Up - 7
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ***** *** ***** ******* *********** ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** **-**, ****** ** *** ******* ********** ****** ********, *****, ***** ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******** ******** ******** ******** ******* *********** ******* *********** *********, *******- ******** *******, **********, *****. ********, *******, *********** ******, ***** (***) ***
****** ******** ******** ******* *************** ******* ******* *********** ****** **. ***/* & ***/**, ******* *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ***** ***** ******** *** *** *************** **., ***. *********** **.*, ******** ****, ***** ****,****** ********, ********, ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.